|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-11-30
|
|
pubmed:abstractText |
This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0002-953X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
158
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2071-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11729030-Adult,
pubmed-meshheading:11729030-Antipsychotic Agents,
pubmed-meshheading:11729030-Cognition Disorders,
pubmed-meshheading:11729030-Double-Blind Method,
pubmed-meshheading:11729030-Drug Therapy, Combination,
pubmed-meshheading:11729030-Eicosapentaenoic Acid,
pubmed-meshheading:11729030-Female,
pubmed-meshheading:11729030-Humans,
pubmed-meshheading:11729030-Male,
pubmed-meshheading:11729030-Middle Aged,
pubmed-meshheading:11729030-Neurologic Examination,
pubmed-meshheading:11729030-Psychiatric Status Rating Scales,
pubmed-meshheading:11729030-Psychotic Disorders,
pubmed-meshheading:11729030-Schizophrenia,
pubmed-meshheading:11729030-Schizophrenic Psychology,
pubmed-meshheading:11729030-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
|
|
pubmed:affiliation |
NIMH, NIH, Bethesda, MD 20892-9621, USA. wfenton@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
